Skip to content

TTNS vs PTNS in a County Hospital System.

Assessment of Patient Satisfaction With Transcutaneous Tibial Nerve Stimulation in a County Hospital System

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07353944
Enrollment
70
Registered
2026-01-21
Start date
2017-01-18
Completion date
2018-06-30
Last updated
2026-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive Bladder

Keywords

overactive bladder, OAB, PTNS, percutaneous tibial nerve stimulation, TTNS, transcutaneous tibial nerve stimulation, county hospital, underserved

Brief summary

The goal of this clinical trial is to study whether transcutaneous tibial nerve stimulation (TTNS) is a feasible and satisfactory treatment for overactive bladder in Urogynecology patients who receive their care at a county hospital. Researchers will compare outcomes with TTNS to patients who undergo percutaneous tibial nerve stimulation (PTNS). The main questions it aims to answer are: * Is TTNS non-inferior to PTNS in terms of OAB symptom severity? * Are patients as satisfied with TTNS as they are with PTNS? * Are patients' symptoms improved with TTNS? Participants will: * either undergo PTNS or be taught how to do TTNS therapy at home * complete surveys about their bladder symptoms and satisfaction with treatment

Detailed description

Patients who consent to this study will be randomly assigned to either receive PTNS in clinic weekly, or TTNS every other day at home. The severity of their overactive bladder symptoms and satisfaction with treatment will be assessed before starting treatment as well as 6 weeks, 12 weeks and 6 months after starting treatment. The results of these surveys will be compared between groups to determine whether TTNS is non-inferior to PTNS in this particular patient population.

Interventions

neuromodulation therapy for overactive bladder that targets the posterior tibial nerve

Sponsors

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

After randomization, patients and care providers will not be blinded, however investigators will be blinded to the results of the survey instruments.

Intervention model description

Randomized control trial

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* age between 18 - 90 years old * patient of the Urogynecology clinic at Harbor UCLA medical center * diagnosis of overactive bladder * patient elects non-pharmacologic treatment of overactive bladder * English or Spanish speaking * able to consent and participate in research

Exclusion criteria

* cognitive impairment or diagnosis of dementia * diagnosis of neurogenic bladder * prior midurethral sling procedure * use of an electronic pacemaker * current pregnancy * incarcerated persons

Design outcomes

Primary

MeasureTime frameDescription
ICIQ-OAB scoreBaseline, 6 weeks, 12 weeks, 6 months post treatment initiationOAB symptom severity

Secondary

MeasureTime frameDescription
Patient satisfaction6 weeks, 12 weeks, 6 months post treatment initiationPatient satisfaction with the intervention (Y/N; would you recommend it to others?)
PGI-I6 weeks, 12 weeks, 6 months post treatment initiationPatient global assessment of overall improvement, graded on a scale of 1-7
Compliance6 months post treatment initiationNumber and percentage of PTNS visits (PTNS arm); Patient reported number of self-administered TTNS treatments per week

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026